Breaking News Instant updates and real-time market news.

ABT

Abbott

09:29
10/19/16
10/19
09:29
10/19/16
09:29

Abbott sees Q4 adjusted EPS of 64c-66c, consensus 65c

Abbott sees operational sales growth of mid single digits in the fourth quarter. For established pharmaceuticals, Abbott sees high-single-digit sales growth in Q4. In nutrition, Abbott sees Q4 sales growth similar to the third quarter. In diagnostics, Abbott sees mid-single-digit growth in Q4. In medical devices: for vascular Abbott sees mid-single-digit sales growth; in diabetes care, sees double-digit sales growth; in medical optics, sees low- to mid-single-digit sales growth. Guidance issued earlier on Q3 earnings call.

  • 19

    Oct

  • 21

    Oct

  • 06

    Nov

ABT Abbott

10/11/16
COWN
10/11/16
NO CHANGE
Target $85
COWN
Outperform
Cowen says St. Jude advisory common for the industry
While Dear Doctor letters are never a positive, St. Jude Medical's (STJ) medical device advisory relating to a low rate of premature battery depletion in the high voltage portfolio is common in the Cardiac Rhythm Management industry, Cowen analyst Joshua Jennings tells investors in a research note. The analyst sees limited risk to St. Jude's franchise and still expects the takeover by Abbott Laboratories' (ABT) to close by the end of the year. Jennings keeps an Outperform rating on St. Jude shares with an $85 price target. The stock is down 1% to $80.19 in pre-market trading.
09/29/16
BARD
09/29/16
NO CHANGE
BARD
Dexcom, Insulet could be weighed down by competitive concerns, says Baird
Baird analyst Jeff Johnson said that while the FDA approvals announced yesterday for Abbott's (ABT) FreeStyle Libre Pro and Medtronic's (MDT) 670G were largely anticipated, he believes that both approvals came sooner than most expected, as did news that Abbott also recently filed for FDA approval of its consumer Libre system. The approvals could "change the narrative" in diabetes and could weigh on others in the sector in the near-term, most notably Dexcom (DXCM) and Insulet (PODD), Johnson tells investors. He keeps Neutral ratings on both and maintains an Overweight rating on Tandem Diabetes (TNDM), citing valuation for the difference.
09/29/16
ADAM
09/29/16
NO CHANGE
Target $53
ADAM
Buy
Alere risk-reward looks 'quite good' as deal debate nears end, says Canaccord
Canaccord analyst Mark Massaro said he is optimistic that a conclusion of Abbott (ABT) and Alere's (ALR) merger fight is "not far off" and he still believes Abbott will ultimately acquire Alere, though he also thinks the merger may be decided by a judge. Massaro puts a 65% probability on the likelihood the deal closes at the $56 deal price, a 30% chance that Abbott buys Alere at a lower price nearer to $50 per share, and only a 5% chance the deal breaks, making the risk-reward ratio in Alere shares at current levels "quite good," he tells investors. He trimmed his price target on Alere to $53 from $56 an keeps a Buy rating on the stock.
09/29/16
COWN
09/29/16
NO CHANGE
COWN
Outperform
Cowen says views on Dexcom, Insulet not changed by competitor launches
Cowen analyst Doug Schenkel noted that Abbott (ABT) announced yesterday it had received FDA approval for the professional version of its FreeStyle Libre glucose monitoring product and filed the consumer version of Libre, while Medtronic (MDT) also announced FDA approval of its 670G Hybrid Closed Loop system. Schenkel said Abbott's consumer Libre filing comes a few months ahead of his expectations but that Medtronic's timing was in-line with expectations. The analyst said the competitor announcements, which had been expected, do not change his views on DexCom (DXCM), Insulet (PODD), or Tandem Diabetes (TNDM) and he keeps Outperform ratings on all three of those stocks.

TODAY'S FREE FLY STORIES

VNCE

Vince Holding

$4.55

0.35 (8.33%)

20:25
12/07/16
12/07
20:25
12/07/16
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 09

    Jan

NWBO

Northwest Biotherapeutics

$0.55

0.0227 (4.33%)

20:17
12/07/16
12/07
20:17
12/07/16
20:17
Hot Stocks
Northwest Biotherapeutics to delist from Nasdaq, confirms clinical trial plans »

Northwest Biotherapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$111.03

1.08 (0.98%)

, MSFT

Microsoft

$61.37

1.42 (2.37%)

20:07
12/07/16
12/07
20:07
12/07/16
20:07
Periodicals
NHL in negotiations to bring Apple devices to team benches, TSN says »

The NHL has told teams it…

AAPL

Apple

$111.03

1.08 (0.98%)

MSFT

Microsoft

$61.37

1.42 (2.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 13

    Mar

ATKR

Atkore

$19.71

-0.11 (-0.55%)

19:59
12/07/16
12/07
19:59
12/07/16
19:59
Syndicate
Atkore 8M share Secondary priced at $19.00 »

Credit Suisse, Deutsche…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

BPMC

Blueprint Medicines

$26.20

-2.23 (-7.84%)

19:58
12/07/16
12/07
19:58
12/07/16
19:58
Syndicate
Blueprint Medicines 5M share Secondary priced at $25.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

LULU

lululemon

$59.84

2.6 (4.54%)

19:50
12/07/16
12/07
19:50
12/07/16
19:50
Hot Stocks
lululemon CFO says early Q4 trends strengthened into December »

Speaking during the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 09

    Jan

LULU

lululemon

$59.84

2.6 (4.54%)

19:50
12/07/16
12/07
19:50
12/07/16
19:50
Hot Stocks
lululemon CEO highlights Q3 gross margin, reports 11% comp growth in pants »

Speaking during the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 09

    Jan

CVX

Chevron

$114.44

1.68 (1.49%)

19:20
12/07/16
12/07
19:20
12/07/16
19:20
Hot Stocks
Chevron announces $19.8B capital, exploratory budget for 2017 »

Chevron announced a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

X

U.S. Steel

$37.49

1.54 (4.28%)

18:49
12/07/16
12/07
18:49
12/07/16
18:49
Periodicals
U.S. Steel CEO: Company may bring back 10,000 U.S. jobs, CNBC says »

U.S. Steel could bring…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VNDA

Vanda

$15.40

-0.6 (-3.75%)

18:47
12/07/16
12/07
18:47
12/07/16
18:47
Hot Stocks
Vanda settles Fanapt patent litigation with Apotex »

Vanda Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AE

Adams Resources

$42.31

-0.68 (-1.58%)

, SWN

Southwestern Energy

$12.37

-0.08 (-0.64%)

18:46
12/07/16
12/07
18:46
12/07/16
18:46
Hot Stocks
Adams Resources appoints Josh Anders as CFO »

Adams Resources &…

AE

Adams Resources

$42.31

-0.68 (-1.58%)

SWN

Southwestern Energy

$12.37

-0.08 (-0.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EZPW

EZCORP

$11.80

0.05 (0.43%)

18:42
12/07/16
12/07
18:42
12/07/16
18:42
Earnings
EZCORP reports Q4 EPS with items (31c), may not compare to consensus 6c »

EPS figure includes…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

RICE

Rice Energy

$24.59

-0.16 (-0.65%)

18:33
12/07/16
12/07
18:33
12/07/16
18:33
Initiation
Rice Energy initiated  »

Rice Energy initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$770.42

5.7 (0.75%)

18:30
12/07/16
12/07
18:30
12/07/16
18:30
Periodicals
Amazon spokesperson denies 2,000 grocery stores report, CNET says »

Following a report by the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ICON

Iconix Brand

$9.26

0.14 (1.54%)

18:23
12/07/16
12/07
18:23
12/07/16
18:23
Hot Stocks
Iconix Brand reports employment termination of Chief Strategy Officer Blumberg »

Iconix Brand disclosed in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PBYI

Puma Biotechnology

$39.80

-2 (-4.78%)

18:23
12/07/16
12/07
18:23
12/07/16
18:23
Hot Stocks
Puma Biotechnology 'pleased' to complete biomarker analysis of neratinib »

Puma Biotechnology…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FTK

Flotek

$11.10

-2.01 (-15.33%)

18:17
12/07/16
12/07
18:17
12/07/16
18:17
Hot Stocks
Flotek: Reviewing FourWorld Capital short report, remain confident in product »

Speaking earlier during…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 07

    Dec

PBYI

Puma Biotechnology

$39.80

-2 (-4.78%)

18:09
12/07/16
12/07
18:09
12/07/16
18:09
Hot Stocks
Puma Biotechnology 'pleased' with preliminary neratinib activity »

Puma Biotechnology…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PNM

PNM Resources

$32.05

0.45 (1.42%)

18:09
12/07/16
12/07
18:09
12/07/16
18:09
Hot Stocks
PNM Resources requests an electric rate increase of $99M in New Mexico »

PNM Resources' New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

BK

BNY Mellon

$48.55

0.56 (1.17%)

18:03
12/07/16
12/07
18:03
12/07/16
18:03
Periodicals
BNY Mellon outage led to certain Swift payment failures, WSJ reports »

Bank of New York Mellon…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TLRD

Tailored Brands

$18.93

0.62 (3.39%)

17:52
12/07/16
12/07
17:52
12/07/16
17:52
Hot Stocks
Tailored Brands up 22% to $23.20 after Q3 results beat estimates »

The company also raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

FLXS

Flexsteel Industries

$59.12

2.92 (5.20%)

, UNH

UnitedHealth

$159.40

2.08 (1.32%)

17:50
12/07/16
12/07
17:50
12/07/16
17:50
Hot Stocks
Flexsteel names Eric Rangen chair of the board »

Flexsteel Industries…

FLXS

Flexsteel Industries

$59.12

2.92 (5.20%)

UNH

UnitedHealth

$159.40

2.08 (1.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NKE

Nike

$52.10

1.53 (3.03%)

, UA

Under Armour

$27.03

1.62 (6.38%)

17:49
12/07/16
12/07
17:49
12/07/16
17:49
Periodicals
Nike losing market share to faster-growing rivals, Barron's reports »

Despite being down nearly…

NKE

Nike

$52.10

1.53 (3.03%)

UA

Under Armour

$27.03

1.62 (6.38%)

ADDYY

adidas

$76.96

1.225 (1.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Dec

T

AT&T

$40.45

1.1 (2.80%)

17:45
12/07/16
12/07
17:45
12/07/16
17:45
Conference/Events
AT&T management to meet with Jefferies »

Group dinner to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 07

    Dec

  • 07

    Dec

EFC

Ellington Financial

$16.30

0.2 (1.24%)

17:41
12/07/16
12/07
17:41
12/07/16
17:41
Hot Stocks
Ellington Financial reports estimated book value per share $19.80 as of Nov 30 »

Ellington Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.